BioNTech在中国收购肿瘤学产品线

IF 33.1 1区 生物学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
{"title":"BioNTech在中国收购肿瘤学产品线","authors":"","doi":"10.1038/s41587-024-02518-3","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"42 12","pages":"1761-1761"},"PeriodicalIF":33.1000,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"BioNTech boosts oncology pipeline with China buy\",\"authors\":\"\",\"doi\":\"10.1038/s41587-024-02518-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19084,\"journal\":{\"name\":\"Nature biotechnology\",\"volume\":\"42 12\",\"pages\":\"1761-1761\"},\"PeriodicalIF\":33.1000,\"publicationDate\":\"2024-12-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature biotechnology\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://www.nature.com/articles/s41587-024-02518-3\",\"RegionNum\":1,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature biotechnology","FirstCategoryId":"5","ListUrlMain":"https://www.nature.com/articles/s41587-024-02518-3","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

在与处于临床阶段的Biotheus合作开发靶向PD-L1和VEGF-A的双特异性抗体一年后,BioNTech宣布以8亿美元的价格收购这家位于中国珠海的公司,其中高达1.5亿美元的潜在里程碑付款。此次收购使BioNTech获得了Biotheus主要候选药物PM8002(也称为BNT327)的全部全球权利;在临床开发的不同阶段的十个项目的管道;还有最先进的生物制剂生产设施。在中国的2期临床试验中,BNT327显示出积极的安全性,并通过将抗vegf活性富集到肿瘤微环境中来促进抗肿瘤活性。BioNTech首席执行官兼联合创始人Uğur Şahin在公司新闻发布会上表示:“收购Biotheus是基于我们在BNT327/PM8002和其他研究性双特异性抗体方面的成功合作。”“我们相信BNT327/PM8002有潜力超越传统的检查点抑制剂,在多种肿瘤适应症中树立新的护理标准。”这些检查点抑制剂包括Keytruda (pembrolizumab),仅默克公司每年就为其带来250亿美元的收入,而Bristol Myers Squibb的Opdivo (nivolumab)和Roche的Tecentriq (atezolizumab)在2023年分别创造了90亿美元和40亿美元的收入。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
BioNTech boosts oncology pipeline with China buy
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nature biotechnology
Nature biotechnology 工程技术-生物工程与应用微生物
CiteScore
63.00
自引率
1.70%
发文量
382
审稿时长
3 months
期刊介绍: Nature Biotechnology is a monthly journal that focuses on the science and business of biotechnology. It covers a wide range of topics including technology/methodology advancements in the biological, biomedical, agricultural, and environmental sciences. The journal also explores the commercial, political, ethical, legal, and societal aspects of this research. The journal serves researchers by providing peer-reviewed research papers in the field of biotechnology. It also serves the business community by delivering news about research developments. This approach ensures that both the scientific and business communities are well-informed and able to stay up-to-date on the latest advancements and opportunities in the field. Some key areas of interest in which the journal actively seeks research papers include molecular engineering of nucleic acids and proteins, molecular therapy, large-scale biology, computational biology, regenerative medicine, imaging technology, analytical biotechnology, applied immunology, food and agricultural biotechnology, and environmental biotechnology. In summary, Nature Biotechnology is a comprehensive journal that covers both the scientific and business aspects of biotechnology. It strives to provide researchers with valuable research papers and news while also delivering important scientific advancements to the business community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信